A Phase IIa Multicenter, Open-label, 12-week Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype
Latest Information Update: 12 Sep 2025
At a glance
- Drugs Alogabat (Primary)
- Indications Angelman syndrome
- Focus Adverse reactions; Pharmacokinetics
- Acronyms Aldebaran
- Sponsors Roche
Most Recent Events
- 05 Aug 2025 Status changed from recruiting to active, no longer recruiting.
- 28 Jul 2025 Planned End Date changed from 4 Nov 2025 to 4 Dec 2025.
- 28 Jul 2025 Planned primary completion date changed from 4 Nov 2025 to 4 Dec 2025.